Description:
Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.
IC50 & Target:
VEGF
In Vitro:
Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity, and inhibits its interaction with VEGFR-1 and VEGFR-2[1]. Experimental analysis shows that the EC50 of Bevacizumab to bind VEGF analyzed by ELISA is 0.18 μg/mL. Binding kinetics assays show similar results that Bevacizumab inhibits the VEGF-induced proliferation of HUVEC with an IC50 value of 0.047±0.0081 μg/mL.
In Vivo:
It is demonstrated that the subconjunctival administration of FD006 and Bevacizumab can significantly inhibit CoNV in NaOH cauterized rats compared with the control group (p < 0.01).
Related Products:
Alirocumab; Denosumab; Eculizumab; Evolocumab; Omalizumab; Ustekinumab; Vedolizumab; Trastuzumab; Omalizumab; Nivolumab; Denosumab; Cetuximab; Aflibercept